Literature DB >> 9865730

Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors.

H Mizuguchi1, T Nakagawa, S Toyosawa, M Nakanishi, S Imazu, T Nakanishi, Y Tsutsumi, S Nakagawa, T Hayakawa, N Ijuhin, T Mayumi.   

Abstract

We report that tumor necrosis factor (TNF) alpha induced a strong antitumor immune reaction when it was produced in arteries leading to tumors by gene transfer in vivo. We used a mouse model carrying a sarcoma-180 tumor in the right footpad and injected the fusogenic liposomes encapsulating the human TNF-alpha gene into the right femoral artery. Under this condition, human TNF-alpha was detected only in the artery leading to the tumor and in the tumor. There was a significant regression in tumor growth when the TNF-alpha gene was delivered into the right femoral artery, with 4 of 11 mice completely cured. No regression was observed when the TNF-alpha gene was delivered into the left femoral artery or into the tumor or when the luciferase gene was administered. Tumor regression was inhibited by the injection of anti-TNF-alpha, anti-CD4, or anti-CD8 monoclonal antibody, and CD8+ T cells accumulated in the tumors of TNF-alpha-treated mice. These results suggest that TNF-alpha expressed locally in the arteries leading to tumors efficiently suppresses tumor growth through reinforcement of an antitumor immune reaction. The significance of this phenomenon for cancer gene therapy was discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865730

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 2.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

3.  Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors.

Authors:  Yuka Okada; Naoki Okada; Shinsaku Nakagawa; Hiroyuki Mizuguchi; Koichi Takahashi; Nobuyasu Mizuno; Takuya Fujita; Akira Yamamoto; Takao Hayakawa; Tadanori Mayumi
Journal:  Jpn J Cancer Res       Date:  2002-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.